论文部分内容阅读
目的观察水飞蓟宾葡甲胺片(协力甘宝)在治疗早期糖尿病肾病(DN)中,对尿微量白蛋白的作用及不良反应。方法64例早期DN患者随机分为治疗组和对照组,同样条件治疗下,治疗组加用水飞蓟宾葡甲胺治疗12周。观察两组治疗前后尿微量白蛋白排泄率(UAER)的变化。结果1.治疗组(水飞蓟宾组)治疗前后差异有统计学意义(P<0.01),对照组治疗前后差异无统计学意义(P>0.01),两组比较差异有统计学意义(P<0.01)。2.治疗组血脂下降无统计学意义。3.治疗组ALT下降,对照组无改变,两组比较,差异有统计学意义(P<0.01)。4.两组观察中血糖平稳,未见其他不良反应。结论水飞蓟宾葡甲胺(协力甘宝)可降低UAER、ALT,同时有一定的调脂作用,未见不良反应。
Objective To observe the effect and side effects of silybin meglumine (synergistic Ganbao) on urinary albumin in the treatment of early diabetic nephropathy (DN). Methods Sixty-four patients with early DN were randomly divided into treatment group and control group. Under the same conditions, the patients in the treatment group were given silibinin for 12 weeks. The changes of urinary albumin excretion rate (UAER) before and after treatment were observed. Results 1. The treatment group (silybin group) had significant difference before and after treatment (P <0.01), there was no significant difference in the control group before and after treatment (P> 0.01), the difference between the two groups was statistically significant (P <0.01). 2. The treatment group, no significant decrease in blood lipids. The treatment group ALT decreased, the control group had no change, the two groups, the difference was statistically significant (P <0.01). 4. Two groups observed in stable blood glucose, no other adverse reactions. Conclusion Silybin meglumine (synergistic Gan Bao) can reduce UAER, ALT, at the same time have a certain lipid-lowering effect, no adverse reactions.